Zydus Lifesci.
Zydus Lifesciences Q2 FY26 earnings call: Revenue & Margins
Q2 FY26 earnings call: what management said on revenue, margins and capex.
Guidance rank: #54 of 83 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
The short version
US business expects sustained long-term growth with 25+ product launches planned this year; base business remains stable with single-digit price erosion. The company maintains a strong growth momentum with consistent performance across segments, aiming to achieve targeted top-line growth and profitability for the fiscal year.
From Zydus Lifesci.'s Q2 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- US business expects sustained long-term growth with 25+ product launches planned this year; base business remains stable with single-digit price erosion.
- Specialty portfolio, including 505(b)(2) injectables like Beizray, to scale meaningfully over next 2-3 years.
- Branded formulations in India growing ahead of market at 9% YoY, driven by chronic, cardiology, gynecology, and oncology therapies.
- Consumer wellness (Comfort Click acquisition) targets strong growth via market expansion in Europe, Middle East, US, and scaling pediatric and pet supplement brands.
- International formulations business growing in strong double digits, driven by emerging markets and Europe.
- Vaccine business expected to become a meaningful part of revenue in 2 years; participating in global tenders by FY27-28.
2 more points from Zydus Lifesci.'s call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Zydus Lifesci. said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The company is investing in building a nephrology facility to produce high-end membranes for dialysis to meet global demand.
- Investments were made in acquisitions: Amplitude Surgical (MedTech) and Comfort Click (consumer wellness/D2C platform).
- There is a strategic focus on expanding the MedTech business in cardiology, nephrology, and orthopedics globally.
- Future capex includes commissioning new manufacturing facilities like the nephrology one.
- Plans to scale up Saroglitazar commercialization in the US, which may involve investment in commercial infrastructure, including a 60-80 person field force.
- Focus on innovation and pipeline expansion in specialty pharma and injectables, which may require capital allocation.
2 more points from Zydus Lifesci.'s call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Zydus Lifesci. said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Zydus Lifesci. said on order book & pipeline — free account, 30 seconds.
Zydus Lifesci. — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹7.6K Cr, net profit ₹1.3K Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Zydus Lifesci.'s management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Bajaj Healthcare Ltd (Q2 FY26)
For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p
- Infinium Pharma (Q2 FY26)
Revenue from Operations for H1FY26: Rs 84.05 crore, a 1% YoY increase from Rs 82.98 crore in H1FY25 (Page 22). Key investor presentation takeaways from Infinium
- Wanbury (Q2 FY26)
Q2FY26 Revenue from Operations: ₹160.06 Crore . Key investor presentation takeaways from Wanbury Ltd's Q2 FY26 investor presentation — and how it ranks against
- Balaxi Pharmaceuticals Ltd (Q2 FY26)
Revenue for Q2 FY26: ₹56.17 crore . Key investor presentation takeaways from Balaxi Pharma's Q2 FY26 investor presentation — and how it ranks against sector pee
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Zydus Lifesci. and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Zydus Lifesci. Q2 FY26 results?
US business expects sustained long-term growth with 25+ product launches planned this year; base business remains stable with single-digit price erosion. The company maintains a strong growth momentum with consistent performance across segments, aiming to achieve targeted top-line growth and profitability for the fiscal year.
What is Zydus Lifesci. share price analysis?
Zydus Lifesci. currently shows a neutral. The stock trades at a P/E of 22.9 with a market cap of ₹111,720 Cr. Investors should review the full earnings analysis for detailed insights.
Is Zydus Lifesci. planning capital expenditure?
The company is investing in building a nephrology facility to produce high-end membranes for dialysis to meet global demand.
Keep Zydus Lifesci. on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.